NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球產前和新生兒基因檢測市場(2021-2027):市場預測(按產品類型、組織類別、最終用戶)、COVID-19 的影響、區域前景、增長潛力、價格趨勢、市場份額

Prenatal and New-born Genetic Testing Market Size By Technology, By Disease, By End-use, COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

出版商 Global Market Insights Inc. 商品編碼 1016673
出版日期 內容資訊 英文 190 Pages
商品交期: 2-3個工作天內
價格
全球產前和新生兒基因檢測市場(2021-2027):市場預測(按產品類型、組織類別、最終用戶)、COVID-19 的影響、區域前景、增長潛力、價格趨勢、市場份額 Prenatal and New-born Genetic Testing Market Size By Technology, By Disease, By End-use, COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027
出版日期: 2021年06月29日內容資訊: 英文 190 Pages
簡介

產前和新生兒基因檢測市場預計到 2027 年將顯著增長。

消費者對遺傳性疾病早期檢測和治療益處的認識不斷提高,預計將推動市場增長。此外,積極研究集成先進技術以提高測試結果也支持市場的進一步發展。

從技術上看,篩選行業佔有很大的份額,預計到 2027 年將增長到約 61 億美元。對與侵入性基因檢測相關的併發症的擔憂正在推動全球對微創產前檢測的需求,從而推動該行業的增長。

本報告探索了全球產前和新生兒基因檢測市場,定義和概述了市場,分析了新型冠狀病毒感染(COVID-19)和其他市場影響因素,以及監管環境。總結了市場規模的變化和預測, 按技術、疾病、最終用戶、地區/主要國家、市場份額、競爭環境等各種類別細分。

第一章調查方法/調查範圍

第 2 章執行摘要

第三章產業考量

  • 行業分類
  • 行業情況
  • 行業影響因素
    • 增長因素
    • 潛在風險和挑戰
  • 增長潛力
  • COVID-19:影響分析
  • 監管狀態
  • 波特分析
  • 競爭形勢
  • PESTEL 分析

第 4 章市場分析/預測:按技術

  • 篩選
    • 絨毛取樣
    • 母體血清篩查
    • 羊膜穿刺術
    • 無創產前檢測
    • 其他
  • 診斷
    • mmPCR
    • 分光光度計
    • 檢測
    • 其他

第 5 章市場分析/預測:按疾病分類

  • 唐氏綜合症
  • 苯丙酮尿症
  • 囊性纖維化
  • 鐮狀細胞性貧血
  • 其他

第 6 章市場分析/預測:按最終用戶

  • 醫院
  • 產科診所/專科診所
  • 診斷中心

第 7 章市場分析/預測:按地區/主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第八章公司簡介

  • 競爭儀表板
  • Abbott
  • Agilent
  • AutoGenomics
  • Ariosa Diagnostics
  • Baebies
  • Berry Genomics Co. Ltd
  • BGI
  • Biocartis Group NV
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc
  • Laboratory Corporation of America
  • Masimo Corporation
  • Natera, Inc.
  • PerkinElmer, Inc
  • Progenity, Inc.
  • Qiagen
  • Sequenom, Inc.
  • Trivitron Healthcare Private Limited
目錄
Product Code: 1906

The prenatal and new-born genetic testing market is projected to exhibit substantial growth by 2027 driven by surging consumer awareness regarding the benefits of early detection and treatment of genetic disorders.

Moreover, increasing research focus on integrating advanced technologies to enhance testing outcomes is also propelling market development. For instance, an October 2020 study by researchers from the University of California showed promising results with the use of high-throughput DNA-sequencing technologies.

The researchers found that the technique called "exome sequencing" could enhance prenatal diagnosis as well as pregnancy outcomes in women with an abnormal prenatal ultrasound. The research, which was published in the New England Journal of Medicine (NEJM), found that, in 37 out of 127 cases, genetic diseases were the underlying cause of nonimmune hydrops fetalis (NIHF) - a life-threatening illness wherein there is abnormal fluid collection in the fetus.

Additionally, with the rising significance of prenatal and new-born genetic testing, more illnesses are being recommended for testing. This would allow early detection of genetic diseases and subsequently, prompt treatment for these illnesses.

For instance, in June 2021, it was announced that all babies born in North Carolina would be tested for spinal muscular atrophy (SMA) at birth under the North Carolina Newborn Screening Program. As part of the program, all newborns in the state are screened for numerous genetic diseases like cystic fibrosis and SMA, which is a common cause of death associated with genetic mutation among children, was added to this list of illnesses in May 2021.

Such early detection allows babies to commence treatment before they develop symptoms of a genetic disorder, which could give significantly better outcomes. Thus, prominent benefits of prenatal and new-born genetic testing is fueling its adoption worldwide, thereby bolstering market demand.

The prenatal and new-born genetic testing market has been segmented on the basis of technology, disease, end-use, and region. Based on technology, the market has been segregated into screening and diagnostic.

In 2020, the screening sub-segment held a significant share in the prenatal and new-born genetic testing market and is expected to be valued at around USD 6.1 billion by 2027. Rising demand for minimally-invasive prenatal testing across the globe owing to complications associated with invasive genetic testing is projected to support segmental adoption through the forecast period.

In terms of disease, the market has been divided into phenylketonuria, Down syndrome, sickle cell anemia, cystic fibrosis, and others. The phenylketonuria sub-segment accounted for a significant market share in 2020 and is anticipated to surpass a valuation of USD 1 billion by 2027. High prevalence of phenylketonuria, along with government initiatives to promote screening and diagnostics for early detection of phenylketonuria, is likely to fuel segmental growth over the analysis period.

Based on end-use, the market has further been segmented into maternity & specialty clinics, hospitals, and diagnostic centers. The maternity & specialty clinics sub-segment is anticipated to witness robust growth to reach a valuation of about USD 3.2 billion by 2027. Rising number of preterm births, high prenatal mortality rate, and increasing demand for prenatal care are speculated to facilitate segmental expansion over the following years.

On the regional spectrum, the Middle East & Africa prenatal and new-born genetic testing market valuation exceeded USD 80 million in 2020 and is projected to witness significant growth over 2021-2027. Augmenting prevalence of birth defects among newborns and growing frequency of chromosomal abnormalities in the fetus across the region are set to foster market outlook in the future.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definition
  • 1.2 Base estimates and working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Prenatal and new-born genetic testing industry 360 degree synopsis, 2016 - 2027
    • 2.1.1 Business trends
    • 2.1.2 Technology trends
    • 2.1.3 Disease trends
    • 2.1.4 End-use trends
    • 2.1.5 Regional trends

Chapter 3 Prenatal and New-born Genetic Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027 (USD Million)
  • 3.3 Industry impact factors
    • 3.3.1 Growth drivers
      • 3.3.1.1 Technological advancements and increasing benefits in the field of prenatal testing and new-born genetic screening
      • 3.3.1.2 Increasing prevalence of genetic disorders and chromosomal abnormalities
      • 3.3.1.3 Rising consanguineous relations
      • 3.3.1.4 Government initiatives and support for prenatal testing and new-born genetic screening
      • 3.3.1.5 Rise in adoption of Non-invasive Prenatal Testing
    • 3.3.2 Industry pitfalls and challenges
      • 3.3.2.1 Increasing false results for prenatal tests
      • 3.3.2.2 Lack of advanced infrastructure and skilled labor
      • 3.3.2.3 Ethical issues to prenatal testing and new-born genetic screening
  • 3.4 Growth potential analysis
    • 3.4.1 By technology
    • 3.4.2 By disease
    • 3.4.3 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Porter's analysis
  • 3.8 Competitive landscape, 2020
    • 3.8.1 Company matrix analysis, 2020
  • 3.9 PESTEL analysis

Chapter 4 Prenatal and New-born Genetic Testing Market, By Technology

  • 4.1 Key segment trends
  • 4.2 Screening
    • 4.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.2 Chorionic Villus Sampling
      • 4.2.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.3 Maternal Serum Screening
      • 4.2.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.4 Amniocentesis
      • 4.2.4.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.5 Non-invasive Prenatal Testing
      • 4.2.5.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.6 Others
      • 4.2.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.3 Diagnostic
    • 4.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.2 mmPCR
      • 4.3.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.3 Spectrophotometer
      • 4.3.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.4 FISH
      • 4.3.4.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.5 Assays
      • 4.3.5.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.6 Others
      • 4.3.6.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 5 Prenatal and New-born Genetic Testing Market, By Disease

  • 5.1 Key segment trends
  • 5.2 Down's Syndrome
    • 5.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.3 Phenylketonuria
    • 5.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.4 Cystic Fibrosis
    • 5.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.5 Sickle Cell Anaemia
    • 5.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.6 Others
    • 5.6.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 6 Prenatal and New-born Genetic Testing Market, By End-use

  • 6.1 Key segment trends
  • 6.2 Hospitals
    • 6.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.3 Maternity and Specialty Clinics
    • 6.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.4 Diagnostic Centers
    • 6.4.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 7 Prenatal and New-born Genetic Testing Market, By Region

  • 7.1 Key regional trends
  • 7.2 North America
    • 7.2.1 Market size, by country, 2016 - 2027 (USD Million)
    • 7.2.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 7.2.2.1 Market size, by screening, 2016 - 2027 (USD Million)
      • 7.2.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
    • 7.2.3 Market size, by disease, 2016 - 2027 (USD Million)
    • 7.2.4 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.2.5 U.S.
      • 7.2.5.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.2.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.2.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.2.5.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.2.5.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.2.6 Canada
      • 7.2.6.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.2.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.2.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.2.6.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.2.6.3 Market size, by end-use, 2016 - 2027 (USD Million)
  • 7.3 Europe
    • 7.3.1 Market size, by country, 2016 - 2027 (USD Million)
    • 7.3.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 7.3.2.1 Market size, by screening, 2016 - 2027 (USD Million)
      • 7.3.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
    • 7.3.3 Market size, by disease, 2016 - 2027 (USD Million)
    • 7.3.4 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.3.5 Germany
      • 7.3.5.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.3.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.3.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.3.5.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.3.5.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.3.6 UK
      • 7.3.6.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.3.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.3.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.3.6.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.3.6.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.3.7 France
      • 7.3.7.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.3.7.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.3.7.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.3.7.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.3.7.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.3.8 Italy
      • 7.3.8.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.3.8.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.3.8.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.3.8.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.3.8.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.3.9 Spain
      • 7.3.9.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.3.9.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.3.9.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.3.9.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.3.9.3 Market size, by end-use, 2016 - 2027 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Market size, by country, 2016 - 2027 (USD Million)
    • 7.4.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 7.4.2.1 Market size, by screening, 2016 - 2027 (USD Million)
      • 7.4.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
    • 7.4.3 Market size, by disease, 2016 - 2027 (USD Million)
    • 7.4.4 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.4.5 China
      • 7.4.5.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.4.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.4.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.4.5.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.4.5.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.4.6 India
      • 7.4.6.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.4.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.4.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.4.6.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.4.6.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.4.7 Japan
      • 7.4.7.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.4.7.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.4.7.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.4.7.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.4.7.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.4.8 Australia
      • 7.4.8.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.4.8.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.4.8.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.4.8.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.4.8.3 Market size, by end-use, 2016 - 2027 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Market size, by country, 2016 - 2027 (USD Million)
    • 7.5.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 7.5.2.1 Market size, by screening, 2016 - 2027 (USD Million)
      • 7.5.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
    • 7.5.3 Market size, by disease, 2016 - 2027 (USD Million)
    • 7.5.4 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.5.5 Brazil
      • 7.5.5.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.5.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.5.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.5.5.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.5.5.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.5.6 Mexico
      • 7.5.6.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.5.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.5.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.5.6.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.5.6.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.5.7 Argentina
      • 7.5.7.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.5.7.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.5.7.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.5.7.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.5.7.3 Market size, by end-use, 2016 - 2027 (USD Million)
  • 7.6 Middle East and Africa
    • 7.6.1 Market size, by country, 2016 - 2027 (USD Million)
    • 7.6.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 7.6.2.1 Market size, by screening, 2016 - 2027 (USD Million)
      • 7.6.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
    • 7.6.3 Market size, by disease, 2016 - 2027 (USD Million)
    • 7.6.4 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.6.5 South Africa
      • 7.6.5.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.6.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.6.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.6.5.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.6.5.3 Market size, by end-use, 2016 - 2027 (USD Million)
    • 7.6.6 Saudi Arabia
      • 7.6.6.1 Market size, by technology, 2016 - 2027 (USD Million)
        • 7.6.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
        • 7.6.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
      • 7.6.6.2 Market size, by disease, 2016 - 2027 (USD Million)
      • 7.6.6.3 Market size, by end-use, 2016 - 2027 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Competitive dashboard, 2020
  • 8.2 Abbott
    • 8.2.1 Business overview
    • 8.2.2 Financial data
    • 8.2.3 Technology landscape
    • 8.2.4 Strategic outlook
    • 8.2.5 SWOT analysis
  • 8.3 Agilent
    • 8.3.1 Business overview
    • 8.3.2 Financial data
    • 8.3.3 Technology landscape
    • 8.3.4 Strategic outlook
    • 8.3.5 SWOT analysis
  • 8.4 AutoGenomics
    • 8.4.1 Business overview
    • 8.4.2 Financial data
    • 8.4.3 Technology landscape
    • 8.4.4 Strategic outlook
    • 8.4.5 SWOT analysis
  • 8.5 Ariosa Diagnostics
    • 8.5.1 Business overview
    • 8.5.2 Financial data
    • 8.5.3 Technology landscape
    • 8.5.4 Strategic outlook
    • 8.5.5 SWOT analysis
  • 8.6 Baebies
    • 8.6.1 Business overview
    • 8.6.2 Financial data
    • 8.6.3 Technology landscape
    • 8.6.4 Strategic outlook
    • 8.6.5 SWOT analysis
  • 8.7 Berry Genomics Co. Ltd
    • 8.7.1 Business overview
    • 8.7.2 Financial data
    • 8.7.3 Technology landscape
    • 8.7.4 Strategic outlook
    • 8.7.5 SWOT analysis
  • 8.8 BGI
    • 8.8.1 Business overview
    • 8.8.2 Financial data
    • 8.8.3 Technology landscape
    • 8.8.4 Strategic outlook
    • 8.8.5 SWOT analysis
  • 8.9 Biocartis Group NV
    • 8.9.1 Business overview
    • 8.9.2 Financial data
    • 8.9.3 Technology landscape
    • 8.9.4 Strategic outlook
    • 8.9.5 SWOT analysis
  • 8.10 Bio-Rad Laboratories, Inc.
    • 8.10.1 Business overview
    • 8.10.2 Financial data
    • 8.10.3 Technology landscape
    • 8.10.4 Strategic outlook
    • 8.10.5 SWOT analysis
  • 8.11 Illumina, Inc
    • 8.11.1 Business overview
    • 8.11.2 Financial data
    • 8.11.3 Technology landscape
    • 8.11.4 Strategic outlook
    • 8.11.5 SWOT analysis
  • 8.12 Laboratory Corporation of America
    • 8.12.1 Business overview
    • 8.12.2 Financial data
    • 8.12.3 Technology landscape
    • 8.12.4 Strategic outlook
    • 8.12.5 SWOT analysis
  • 8.13 Masimo Corporation
    • 8.13.1 Business overview
    • 8.13.2 Financial data
    • 8.13.3 Technology landscape
    • 8.13.4 Strategic outlook
    • 8.13.5 SWOT analysis
  • 8.14 Natera, Inc.
    • 8.14.1 Business overview
    • 8.14.2 Financial data
    • 8.14.3 Technology landscape
    • 8.14.4 Strategic outlook
    • 8.14.5 SWOT analysis
  • 8.15 PerkinElmer, Inc
    • 8.15.1 Business overview
    • 8.15.2 Financial data
    • 8.15.3 Technology landscape
    • 8.15.4 Strategic outlook
    • 8.15.5 SWOT analysis
  • 8.16 Progenity, Inc.
    • 8.16.1 Business overview
    • 8.16.2 Financial data
    • 8.16.3 Technology landscape
    • 8.16.4 Strategic outlook
    • 8.16.5 SWOT analysis
  • 8.17 Qiagen
    • 8.17.1 Business overview
    • 8.17.2 Financial data
    • 8.17.3 Technology landscape
    • 8.17.4 Strategic outlook
    • 8.17.5 SWOT analysis
  • 8.18 Sequenom, Inc.
    • 8.18.1 Business overview
    • 8.18.2 Financial data
    • 8.18.3 Technology landscape
    • 8.18.4 Strategic outlook
    • 8.18.5 SWOT analysis
  • 8.19 Trivitron Healthcare Private Limited
    • 8.19.1 Business overview
    • 8.19.2 Financial data
    • 8.19.3 Technology landscape
    • 8.19.4 Strategic outlook
    • 8.19.5 SWOT analysis

Data Tables

  • TABLE 1. Prenatal and new-born genetic testing industry 360 degree synopsis, 2016-2027
  • TABLE 2. Global prenatal and new-born genetic testing market, 2016 - 2020 (USD Million)
  • TABLE 3. Global prenatal and new-born genetic testing market, 2021 - 2027 (USD Million)
  • TABLE 4. Global prenatal and new-born genetic testing market, by technology, 2016 - 2020 (USD Million)
  • TABLE 5. Global prenatal and new-born genetic testing market, by technology, 2021 - 2027 (USD Million)
  • TABLE 6. Global prenatal and new-born genetic testing market, by disease, 2016 - 2020 (USD Million)
  • TABLE 7. Global prenatal and new-born genetic testing market, by disease, 2021 - 2027 (USD Million)
  • TABLE 8. Global prenatal and new-born genetic testing market, by end-use, 2016 - 2020 (USD Million)
  • TABLE 9. Global prenatal and new-born genetic testing market, by end-use, 2021 - 2027 (USD Million)
  • TABLE 10. Global prenatal and new-born genetic testing market, by region, 2016 - 2020 (USD Million)
  • TABLE 11. Global prenatal and new-born genetic testing market, by region, 2021 - 2027 (USD Million)
  • TABLE 12. Industry impact forces
  • TABLE 13. Screening market size, by region, 2016 - 2020 (USD Million)
  • TABLE 14. Screening market size, by region, 2021 - 2027 (USD Million)
  • TABLE 15. Chorionic villus sampling market size, by region, 2016 - 2020 (USD Million)
  • TABLE 16. Chorionic villus sampling market size, by region, 2021 - 2027 (USD Million)
  • TABLE 17. Maternal serum screening market size, by region, 2016 - 2020 (USD Million)
  • TABLE 18. Maternal serum screening market size, by region, 2021 - 2027 (USD Million)
  • TABLE 19. Amniocentesis market size, by region, 2016 - 2020 (USD Million)
  • TABLE 20. Amniocentesis market size, by region, 2021 - 2027 (USD Million)
  • TABLE 21. Non-invasive prenatal testing market size, by region, 2016 - 2020 (USD Million)
  • TABLE 22. Non-invasive prenatal testing market size, by region, 2021 - 2027 (USD Million)
  • TABLE 23. Others market size, by region, 2016 - 2020 (USD Million)
  • TABLE 24. Others market size, by region, 2021 - 2027 (USD Million)
  • TABLE 25. Diagnostic market size, by region, 2016 - 2020 (USD Million)
  • TABLE 26. Diagnostic market size, by region, 2021 - 2027 (USD Million)
  • TABLE 27. mmPCR market size, by region, 2016 - 2020 (USD Million)
  • TABLE 28. mmPCR market size, by region, 2021 - 2027 (USD Million)
  • TABLE 29. Spectrophotometer market size, by region, 2016 - 2020 (USD Million)
  • TABLE 30. Spectrophotometer market size, by region, 2021 - 2027 (USD Million)
  • TABLE 31. FISH market size, by region, 2016 - 2020 (USD Million)
  • TABLE 32. FISH market size, by region, 2021 - 2027 (USD Million)
  • TABLE 33. Assays market size, by region, 2016 - 2020 (USD Million)
  • TABLE 34. Assays market size, by region, 2021 - 2027 (USD Million)
  • TABLE 35. Others market size, by region, 2016 - 2020 (USD Million)
  • TABLE 36. Others market size, by region, 2021 - 2027 (USD Million)
  • TABLE 37. Down's syndrome market size, by region, 2016 - 2020 (USD Million)
  • TABLE 38. Down's syndrome market size, by region, 2021 - 2027 (USD Million)
  • TABLE 39. Phenylketonuria market size, by region, 2016 - 2020 (USD Million)
  • TABLE 40. Phenylketonuria market size, by region, 2021 - 2027 (USD Million)
  • TABLE 41. Cystic fibrosis market size, by region, 2016 - 2020 (USD Million)
  • TABLE 42. Cystic fibrosis market size, by region, 2021 - 2027 (USD Million)
  • TABLE 43. Sickle cell anaemia market size, by region, 2016 - 2020 (USD Million)
  • TABLE 44. Sickle cell anaemia market size, by region, 2021 - 2027 (USD Million)
  • TABLE 45. Others market size, by region, 2016 - 2020 (USD Million)
  • TABLE 46. Others market size, by region, 2021 - 2027 (USD Million)
  • TABLE 47. Hospitals market size, by region, 2015 - 2019 (USD Million)
  • TABLE 48. Hospitals market size, by region, 2020 - 2026 (USD Million)
  • TABLE 49. Maternity and specialty clinics market size, by region, 2015 - 2019 (USD Million)
  • TABLE 50. Maternity and specialty clinics market size, by region, 2020 - 2026 (USD Million)
  • TABLE 51. Diagnostic centers market size, by region, 2015 - 2019 (USD Million)
  • TABLE 52. Diagnostic centers market size, by region, 2020 - 2026 (USD Million)
  • TABLE 53. North America prenatal and new-born genetic testing market size, by country, 2016 - 2020 (USD Million)
  • TABLE 54. North America prenatal and new-born genetic testing market size, by country, 2021 - 2027 (USD Million)
  • TABLE 55. North America prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 56. North America prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 57. North America prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 58. North America prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 59. North America prenatal and new-born genetic testing market size, by diagnostics, 2016 - 2020 (USD Million)
  • TABLE 60. North America prenatal and new-born genetic testing market size, by diagnostics, 2021 - 2027 (USD Million)
  • TABLE 61. North America prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 62. North America prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 63. North America prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 64. North America prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 65. U.S. prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 66. U.S. prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 67. U.S. prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 68. U.S. prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 69. U.S. prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 70. U.S. prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 71. U.S. prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 72. U.S. prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 73. U.S. prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 74. U.S. prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 75. Canada prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 76. Canada prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 77. Canada prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 78. Canada prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 79. Canada prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 80. Canada prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 81. Canada prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 82. Canada prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 83. Canada prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 84. Canada prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 85. Europe prenatal and new-born genetic testing market size, by country, 2016 - 2020 (USD Million)
  • TABLE 86. Europe prenatal and new-born genetic testing market size, by country, 2021 - 2027 (USD Million)
  • TABLE 87. Europe prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 88. Europe prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 89. Europe prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 90. Europe prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 91. Europe prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 92. Europe prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 93. Europe prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 94. Europe prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 95. Europe prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 96. Europe prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 97. Germany prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 98. Germany prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 99. Germany prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 100. Germany prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 101. Germany prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 102. Germany prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 103. Germany prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 104. Germany prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 105. Germany prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 106. Germany prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 107. UK prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 108. UK prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 109. UK prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 110. UK prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 111. UK prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 112. UK prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 113. UK prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 114. UK prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 115. UK prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 116. UK prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 117. France prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 118. France prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 119. France prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 120. France prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 121. France prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 122. France prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 123. France prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 124. France prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 125. France prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 126. France prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 127. Italy prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 128. Italy prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 129. Italy prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 130. Italy prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 131. Italy prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 132. Italy prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 133. Italy prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 134. Italy prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 135. Italy prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 136. Italy prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 137. Spain prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 138. Spain prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 139. Spain prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 140. Spain prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 141. Spain prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 142. Spain prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 143. Spain prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 144. Spain prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 145. Spain prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 146. Spain prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 147. Asia Pacific prenatal and new-born genetic testing market size, by country, 2016 - 2020 (USD Million)
  • TABLE 148. Asia Pacific prenatal and new-born genetic testing market size, by country, 2021 - 2027 (USD Million)
  • TABLE 149. Asia Pacific prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 150. Asia Pacific prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 151. Asia Pacific prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 152. Asia Pacific prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 153. Asia Pacific prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 154. Asia Pacific prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 155. Asia Pacific prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 156. Asia Pacific prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 157. Asia Pacific prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 158. Asia Pacific prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 159. China prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 160. China prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 161. China prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 162. China prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 163. China prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 164. China prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 165. China prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 166. China prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 167. China prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 168. China prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 169. India prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 170. India prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 171. India prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 172. India prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 173. India prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 174. India prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 175. India prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 176. India prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 177. India prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 178. India prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 179. Japan prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 180. Japan prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 181. Japan prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 182. Japan prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 183. Japan prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 184. Japan prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 185. Japan prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 186. Japan prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 187. Japan prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 188. Japan prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 189. Australia prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 190. Australia prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 191. Australia prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 192. Australia prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 193. Australia prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 194. Australia prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 195. Australia prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 196. Australia prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 197. Australia prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 198. Australia prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 199. Latin America prenatal and new-born genetic testing market size, by country, 2016 - 2020 (USD Million)
  • TABLE 200. Latin America prenatal and new-born genetic testing market size, by country, 2021 - 2027 (USD Million)
  • TABLE 201. Latin America prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 202. Latin America prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 203. Latin America prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 204. Latin America prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 205. Latin America prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 206. Latin America prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 207. Latin America prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 208. Latin America prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 209. Latin America prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 210. Latin America prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 211. Brazil prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 212. Brazil prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 213. Brazil prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 214. Brazil prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 215. Brazil prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 216. Brazil prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 217. Brazil prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 218. Brazil prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 219. Brazil prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 220. Brazil prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 221. Mexico prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 222. Mexico prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 223. Mexico prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 224. Mexico prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 225. Mexico prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 226. Mexico prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 227. Mexico prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 228. Mexico prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 229. Mexico prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 230. Mexico prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 231. Argentina prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 232. Argentina prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 233. Argentina prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 234. Argentina prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 235. Argentina prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 236. Argentina prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 237. Argentina prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 238. Argentina prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 239. Argentina prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 240. Argentina prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 241. MEA prenatal and new-born genetic testing market size, by country, 2016 - 2020 (USD Million)
  • TABLE 242. MEA prenatal and new-born genetic testing market size, by country, 2021 - 2027 (USD Million)
  • TABLE 243. MEA prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 244. MEA prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 245. MEA prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 246. MEA prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 247. MEA prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 248. MEA prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 249. MEA prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 250. MEA prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 251. MEA prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 252. MEA prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 253. South Africa prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 254. South Africa prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 255. South Africa prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 256. South Africa prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 257. South Africa prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 258. South Africa prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 259. South Africa prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 260. South Africa prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 261. South Africa prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 262. South Africa prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)
  • TABLE 263. Saudi Arabia prenatal and new-born genetic testing market size, by technology, 2016 - 2020 (USD Million)
  • TABLE 264. Saudi Arabia prenatal and new-born genetic testing market size, by technology, 2021 - 2027 (USD Million)
  • TABLE 265. Saudi Arabia prenatal and new-born genetic testing market size, by screening, 2016 - 2020 (USD Million)
  • TABLE 266. Saudi Arabia prenatal and new-born genetic testing market size, by screening, 2021 - 2027 (USD Million)
  • TABLE 267. Saudi Arabia prenatal and new-born genetic testing market size, by diagnostic, 2016 - 2020 (USD Million)
  • TABLE 268. Saudi Arabia prenatal and new-born genetic testing market size, by diagnostic, 2021 - 2027 (USD Million)
  • TABLE 269. Saudi Arabia prenatal and new-born genetic testing market size, by disease, 2016 - 2020 (USD Million)
  • TABLE 270. Saudi Arabia prenatal and new-born genetic testing market size, by disease, 2021 - 2027 (USD Million)
  • TABLE 271. Saudi Arabia prenatal and new-born genetic testing market size, by end-use, 2016 - 2020 (USD Million)
  • TABLE 272. Saudi Arabia prenatal and new-born genetic testing market size, by end-use, 2021 - 2027 (USD Million)

Charts and Figures

  • FIG. 1 Market estimation and forecast methodology
  • FIG. 2 Top-down approach (supply side analysis)
  • FIG. 3 Bottom-up approach (demand side analysis)
  • FIG. 4 Industry segmentation
  • FIG. 5 Global prenatal and new-born genetic testing market size, 2016 - 2027 (USD Million)
  • FIG. 6 Growth potential analysis, by technology
  • FIG. 7 Growth potential analysis, by disease
  • FIG. 8 Growth potential analysis, by end-use
  • FIG. 9 Porter's analysis
  • FIG. 10 Competitive matrix analysis
  • FIG. 11 PESTEL analysis
  • FIG. 12 Key segment trends, by technology
  • FIG. 13 Key segment trends, by disease
  • FIG. 14 Key segment trends, by end-use
  • FIG. 15 Key regional trends